scholarly journals Phosphatidylcholine Transfer Protein Promotes Apolipoprotein A-I-mediated Lipid Efflux in Chinese Hamster Ovary Cells

2001 ◽  
Vol 277 (8) ◽  
pp. 6198-6206 ◽  
Author(s):  
Juan M. Baez ◽  
Suzanne E. Barbour ◽  
David E. Cohen
1997 ◽  
Vol 10 (2) ◽  
pp. 226-236 ◽  
Author(s):  
Hartmut H.-J. Schmidt ◽  
Janine Genschel ◽  
Regina Haas ◽  
Carsten Büttner ◽  
Michael P. Manns

1987 ◽  
Vol 262 (9) ◽  
pp. 4241-4247 ◽  
Author(s):  
J.B. Mallory ◽  
P.J. Kushner ◽  
A.A. Protter ◽  
C.L. Cofer ◽  
V.L. Appleby ◽  
...  

2005 ◽  
Vol 388 (1) ◽  
pp. 57-63 ◽  
Author(s):  
Juan M. BAEZ ◽  
Ira TABAS ◽  
David E. COHEN

Macrophages are the predominant cellular component of atherosclerotic lesions, where they scavenge oxidatively modified lipoproteins while defending themselves against cholesterol-induced cytotoxicity by adaptive mechanisms that depend in part on the synthesis, distribution and efflux of phosphatidylcholines. PC-TP (phosphatidylcholine transfer protein) is a START (steroidogenic acute regulatory protein-related lipid transfer) domain protein that catalyses the intermembrane transfer of phosphatidylcholines and promotes apolipoprotein AI-mediated lipid efflux when overexpressed in the cytosol of Chinese-hamster ovary cells. To explore a role for PC-TP in the adaptive responses of macrophages to cholesterol loading, we utilized peritoneal macrophages from mice with homozygous disruption of the gene encoding PC-TP (Pctp−/−) and wild-type littermate controls. PC-TP was abundantly expressed in macrophages from wild-type but not Pctp−/− mice. In cholesteryl ester-loaded macrophages from Pctp−/− mice, the apolipoprotein AI-mediated efflux of phospholipids and cholesterol was decreased. This could be attributed to proportional decreases in the expression levels of ATP-binding cassette A1. Also, in response to free cholesterol loading, the absence of PC-TP from macrophages was associated with marked increases in apoptotic cell death. These findings suggest that PC-TP in macrophages may serve an atheroprotective role by defending against cholesterol-induced cytotoxicity.


1991 ◽  
Vol 2 (4) ◽  
pp. 296-303 ◽  
Author(s):  
Louise Brissette ◽  
Nicole Cahuzac-Bec ◽  
Marc Desforges ◽  
Jean-Louis Bec ◽  
Yves L. Marcel ◽  
...  

Pathology ◽  
1993 ◽  
Vol 25 (3) ◽  
pp. 268-276 ◽  
Author(s):  
Wanda B. Mackinnon ◽  
Marlen Dyne ◽  
Rebecca Hancock ◽  
Carolyn E. Mountford ◽  
Adrienne J. Grant ◽  
...  

Author(s):  
Shazid Md. Sharker ◽  
Md. Atiqur Rahman

Most of clinical approved protein-based drugs or under in clinical trial have a profound impact in the treatment of critical diseases. The mammalian eukaryotic cells culture approaches, particularly the CHO (Chinese Hamster Ovary) cells are mainly used in the biopharmaceutical industry for the mass-production of therapeutic protein. Recent advances in CHO cell bioprocessing to yield recombinant proteins and monoclonal antibodies have enabled the expression of quality protein. The developments of cell lines are possible to upgrade specific productivity. As a result, it holds an interesting area for academic as well as industrial researchers around the world. This review will concentrate on the recent progress of the mammalian CHO cells culture technology and the future scope of further development for the mass-production of protein therapeutics.


Sign in / Sign up

Export Citation Format

Share Document